At Delta4 we’re always looking for key partnerships that are mutually beneficial. Combining our strengths with those of your pharmaceutical company, university, research organization, etc. we can accelerate progress and accomplish more together.
We support organizations seeking techbio expertise across multiple areas, including:
Disease pathobiology and drug MoA modeling
Drug target identification and prioritization
Drug-centric computational drug repositioning (indication expansion)
Disease-centric drug repositioning
Mechanistic adverse event prediction
Drug combination analysis
Assessment of drug MoA in the context of SoC treatment
Identification and prioritization of biomarkers
Novel Therapies for PBC & PSC
Delta4 and 4P-Pharma are jointly developing novel therapeutic candidates for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), two progressive cholestatic liver diseases with high unmet medical need. Using its Hyper-C platform, Delta4 leads computational compound discovery, candidate prioritization, and mechanism-of-action analysis to identify first-in-class treatment options. Selected compounds from Delta4’s computational ranking are currently being evaluated by 4P-Pharma in preclinical efficacy studies. Initial preclinical results are available. This long-term collaboration combines AI-driven discovery with translational pharmacology to advance disease-modifying therapies toward the clinic.
Personalized Medicine in Chronic Kidney Disease
PICKED is an EU-funded Marie Skłodowska-Curie Doctoral Network advancing personalized medicine in chronic kidney disease (CKD), with a focus on the transition from acute kidney injury (AKI) to CKD. Delta4 plays a central role by uncovering molecular mechanisms of disease progression using its proprietary Hyper-C platform and AI-driven drug repurposing workflows. By analyzing large-scale, multi-omics datasets, Delta4 identifies biomarkers, therapeutic targets, and optimized treatment strategies across disease stages. Close collaboration with experimental and clinical partners enables rapid validation of computational predictions using unpublished consortium data. Together, the consortium accelerates translation of systems-level insights into clinically relevant decision support for nephrology.
Omics-Oriented Intervention in Prostate Cancer
PROMOTE is an EU-funded Marie Skłodowska-Curie Doctoral Network focused on improving clinical management of prostate cancer through omics technologies and artificial intelligence. The project addresses disease progression from early-stage prostate cancer to advanced and metastatic disease, where prognosis remains poor and treatment options are limited. Delta4 contributes AI-powered systems biology analyses using its Hyper-C platform to translate multi-omics data into actionable biomarkers and therapeutic strategies. A central focus of Delta4’s work is the investigation of synthetic lethality to identify gene interactions and rational drug combinations that selectively target cancer cells. Through close collaboration with academic, clinical, and industry partners, PROMOTE accelerates the development of non-invasive diagnostics and molecularly driven therapies for personalized prostate cancer treatment.
Personalized Medicine in Chronic Kidney Disease
PerMediK is an EU-funded COST Action focused on advancing personalized medicine in chronic kidney disease (CKD) through coordinated use of multidimensional omics data and systems biology. Delta4 joined the initiative in 2023, with its Computational Biology Lead representing Austria on the PerMediK Management Committee. The action brings together a pan-European network of experts from nephrology, bioinformatics, biomarker research, and drug development to overcome fragmentation in CKD research. Delta4 contributes computational disease modeling expertise to support harmonized data integration, biomarker translation, and clinically relevant interpretation of large-scale molecular datasets. By fostering structured collaboration and knowledge exchange, PerMediK accelerates the path from Big Data to actionable insights in CKD.
Read our latest insights on AI, innovation, and applied research.
It’s an honor and a privilege to be working with the best of the best!
Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.
“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com
